Tags

Type your tag names separated by a space and hit enter

Coagulation factor VII and inflammatory markers in patients with coronary heart disease.
Blood Coagul Fibrinolysis. 2007 Jul; 18(5):473-7.BC

Abstract

To further elucidate the connection between inflammation and factor VII (FVII) taking genetic variation in the FVII locus into account, we have examined 387 patients after myocardial infarction and 387 age-matched and sex-matched healthy control individuals. Circulating levels of C-reactive protein, FVII antigen (FVIIag), activated FVII (FVIIa), fibrinogen and interleukin-6 were analysed and all subjects were genotyped for the Arg353Gln polymorphism in the FVII locus. Plasma concentrations of C-reactive protein, fibrinogen, and interleukin-6 were higher among patients than control individuals. FVIIag was lower in the patient group, but for FVIIa there was no difference between the two groups. Among the inflammatory markers, only C-reactive protein indicated a weak nonlinear association with FVII. No significant difference in frequency of the Gln allele was observed between patients and control individuals but the presence of the Gln allele was associated with lower plasma levels of FVIIag and FVIIa in both groups. The low-grade chronic inflammation seen 3 months after myocardial infarction is not of major importance for the variation in plasma concentration of FVII. The presence of the Gln allele in the Arg353Gln polymorphism in the FVII locus did not differ between patients and control individuals but was associated with lower plasma levels of FVIIag and FVIIa that could have a protective effect against myocardial infarction. To further elucidate these facts, a prospective study should be performed to reduce the risk of a possible selection bias due to coronary heart disease death seen in retrospective case-control studies.

Authors+Show Affiliations

Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Solna, Sweden. mattias.ekstrom@karolinska.seNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

17581323

Citation

Ekström, Mattias, et al. "Coagulation Factor VII and Inflammatory Markers in Patients With Coronary Heart Disease." Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis, vol. 18, no. 5, 2007, pp. 473-7.
Ekström M, Silveira A, Bennermo M, et al. Coagulation factor VII and inflammatory markers in patients with coronary heart disease. Blood Coagul Fibrinolysis. 2007;18(5):473-7.
Ekström, M., Silveira, A., Bennermo, M., Eriksson, P., & Tornvall, P. (2007). Coagulation factor VII and inflammatory markers in patients with coronary heart disease. Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis, 18(5), 473-7.
Ekström M, et al. Coagulation Factor VII and Inflammatory Markers in Patients With Coronary Heart Disease. Blood Coagul Fibrinolysis. 2007;18(5):473-7. PubMed PMID: 17581323.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coagulation factor VII and inflammatory markers in patients with coronary heart disease. AU - Ekström,Mattias, AU - Silveira,Angela, AU - Bennermo,Marie, AU - Eriksson,Per, AU - Tornvall,Per, PY - 2007/6/22/pubmed PY - 2007/12/28/medline PY - 2007/6/22/entrez SP - 473 EP - 7 JF - Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis JO - Blood Coagul Fibrinolysis VL - 18 IS - 5 N2 - To further elucidate the connection between inflammation and factor VII (FVII) taking genetic variation in the FVII locus into account, we have examined 387 patients after myocardial infarction and 387 age-matched and sex-matched healthy control individuals. Circulating levels of C-reactive protein, FVII antigen (FVIIag), activated FVII (FVIIa), fibrinogen and interleukin-6 were analysed and all subjects were genotyped for the Arg353Gln polymorphism in the FVII locus. Plasma concentrations of C-reactive protein, fibrinogen, and interleukin-6 were higher among patients than control individuals. FVIIag was lower in the patient group, but for FVIIa there was no difference between the two groups. Among the inflammatory markers, only C-reactive protein indicated a weak nonlinear association with FVII. No significant difference in frequency of the Gln allele was observed between patients and control individuals but the presence of the Gln allele was associated with lower plasma levels of FVIIag and FVIIa in both groups. The low-grade chronic inflammation seen 3 months after myocardial infarction is not of major importance for the variation in plasma concentration of FVII. The presence of the Gln allele in the Arg353Gln polymorphism in the FVII locus did not differ between patients and control individuals but was associated with lower plasma levels of FVIIag and FVIIa that could have a protective effect against myocardial infarction. To further elucidate these facts, a prospective study should be performed to reduce the risk of a possible selection bias due to coronary heart disease death seen in retrospective case-control studies. SN - 0957-5235 UR - https://www.unboundmedicine.com/medline/citation/17581323/Coagulation_factor_VII_and_inflammatory_markers_in_patients_with_coronary_heart_disease_ L2 - https://doi.org/10.1097/MBC.0b013e3281a3057f DB - PRIME DP - Unbound Medicine ER -